Literature DB >> 15808681

Xenotransplantation of neonatal porcine liver cells.

O Garkavenko1, D F Emerich, M Muzina, Z Muzina, A V Vasconcellos, A B Ferguson, I J Cooper, R B Elliott.   

Abstract

Xenotransplantation of porcine liver cell types may provide a means of overcoming the shortage of suitable donor tissues to treat hepatic diseases characterized by inherited inborn errors of metabolism or protein production. Here we report the successful isolation, culture, and xenotransplantation of liver cells harvested from 7- to 10-day-old piglets. Liver cells were isolated and cultured immediately after harvesting. Cell viability was excellent (>90%) over the duration of the in vitro studies (3 weeks) and the cultured cells continued to significantly proliferate. These cells also retained their normal secretory and metabolic capabilities as determined by continued release of albumin, factor 8, and indocyanin green (ICG) uptake. After 3 weeks in culture, porcine liver cells were loaded into immunoisolatory macro devices (Theracyte devices) and placed into the intraperitoneal cavity of immunocompetant CD1 mice. Eight weeks later, the devices were retrieved and the cells analyzed for posttransplant determinations of survival and function. Post mortem analysis confirmed that the cell-loaded devices were biocompatible, and were well-tolerated without inducing any notable inflammatory reaction in the tissues immediately surrounding the encapsulated cells. Finally, the encapsulated liver cells remained viable and functional as determined by histologic analyses and ICG uptake/release. The successful harvesting, culturing, and xenotransplantation of functional neonatal pig liver cells support the continued development of this approach for treating a range of currently undertreated or intractable hepatic diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808681     DOI: 10.1016/j.transproceed.2004.12.183

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  Liver volume measurement: reason of the difference between in vivo CT-volumetry and intraoperative ex vivo determination and how to cope it.

Authors:  Stefan M Niehues; J K Unger; M Malinowski; J Neymeyer; B Hamm; M Stockmann
Journal:  Eur J Med Res       Date:  2010-08-20       Impact factor: 2.175

2.  Anti-tumor therapy with macroencapsulated endostatin producer cells.

Authors:  Danielle B Rodrigues; Roger Chammas; Natália V Malavasi; Patrícia L N da Costa; Rosa M Chura-Chambi; Keli N Balduino; Ligia Morganti
Journal:  BMC Biotechnol       Date:  2010-03-02       Impact factor: 2.563

3.  Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies.

Authors:  Seung-Hee Lee; Ergeng Hao; Alexei Y Savinov; Ifat Geron; Alex Y Strongin; Pamela Itkin-Ansari
Journal:  Transplantation       Date:  2009-04-15       Impact factor: 4.939

4.  Real-time bioluminescence imaging of macroencapsulated fibroblasts reveals allograft protection in rhesus monkeys (Macaca mulatta).

Authors:  Alice F Tarantal; C Chang I Lee; Pamela Itkin-Ansari
Journal:  Transplantation       Date:  2009-07-15       Impact factor: 4.939

5.  Xenogeneic cell therapy provides a novel potential therapeutic option for cancers by restoring tissue function, repairing cancer wound and reviving anti-tumor immune responses.

Authors:  Chi-Ping Huang; Chi-Cheng Chen; Chih-Rong Shyr
Journal:  Cancer Cell Int       Date:  2018-01-16       Impact factor: 5.722

6.  Artificial liver research output and citations from 2004 to 2017: a bibliometric analysis.

Authors:  Yan Li; Meizhi He; Ziyuan Zou; Xiaohui Bian; Xiaowen Huang; Chen Yang; Shuyi Wei; Shixue Dai
Journal:  PeerJ       Date:  2019-01-11       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.